Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The Aurora A inhibitor alisertib shows encouraging activities in clinical trials against advanced breast cancer. However, it remains unclear whether and how the inflammatory microenvironment is involved in its efficacy. Here, we demonstrated that inhibition of Aurora A directly reshaped the immune microenvironment through removal of tumor-promoting myeloid cells and enrichment of anticancer T lymphocytes, which established a tumor-suppressive microenvironment and significantly contributed to the regression of murine mammary tumors. Mechanistically, alisertib treatment triggered apoptosis in myeloid-derived suppressor cells (MDSC) and macrophages, resulting in their elimination from tumors. Furthermore, alisertib treatment disrupted the immunosuppressive functions of MDSC by inhibiting Stat3-mediated ROS production. These alterations led to significant increases of active CD8+ and CD4+ T lymphocytes, which efficiently inhibited the proliferation of tumor cells. Intriguingly, alisertib combined with PD-L1 blockade showed synergistic efficacy in the treatment of mammary tumors. These results detail the effects of Aurora A inhibition on the immune microenvironment and provide a novel chemo-immunotherapy strategy for advanced breast cancers. Significance: These findings show that inhibition of Aurora A facilitates an anticancer immune microenvironment, which can suppress tumor progression and enhance anti–PD-L1 therapy in breast cancer. See related commentary by Rivoltini et al., p. 3169
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with this notion, the AURKA inhibitor alisertib appears to promote tumor infiltration of CD8 + T cells via a non-canonical pathway involving IL10 secretion (Han et al., 2020b) and to directly deplete the MDSC compartment of mouse mammary tumors, ultimately mediating an immunotherapeutic effect that can be enhanced by ICIs (Yin et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Yin et al., 2019
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Cited by
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Du, R., Huang, C., Liu, K., Li, X., & Dong, Z. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01305-3 · Cited by 586
STAT proteins in cancer: orchestration of metabolism
Li, Y.-J., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 282
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
Huang, R., Chen, H., Liang, J., Li, Y., Yang, J., Luo, C., Tang, Y., Ding, Y., Liu, X., Yuan, Q., et al. (2021) · Journal of Cancer · doi:10.7150/jca.54699 · Cited by 211
Self-citationLiu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1337 · Cited by 171
Self-citation
Metadata
- Authors
- Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., Ma, X., Liu, C., Liu, S., Lian, Z.-X., & Yang, Z.
- Affiliations
- University of Science and Technology of China (CN)
- 2Chronic Disease Laboratory, Institutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou, China.
- South China University of Technology (CN)
- Fudan University (CN)
- ORCID
- Venue
- Cancer Research
- Published
- 2019-07-01
- Volume
- 79
- Issue
- 13
- Pages
- 3431-3444
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2943638659
- Cited by
- 92
- References
- 50
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 14 · 2023: 17 · 2022: 8 · 2021: 17 · 2020: 13 · 2019: 4
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology (2015CB553804, 2014CB910602, 2017YFA0205600)
- National Natural Science Foundation of China (31701178, 31571396, 31771498, 81430034, 91542123)
- Scientific and Technological projects of Anhui province (1604a0802073)
- Guangdong Introducing Innovative (2017ZT07S054)
- Foundation of Hefei Center for Physical Science and Technology (2016FXCX004)
- Medical Research Fund (WK9110000004)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- alisertib, breast cancer, myeloid-derived suppressor cells, tumor-associated macrophages, immunosuppression, PD-L1 blockade, tumor immune microenvironment, STAT3 signaling, reactive oxygen species, T cell activation, chemoimmunotherapy, combination therapy
- MeSH terms
- Animals, Breast Neoplasms, Humans, Myeloid Cells, Mice, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Aurora Kinase A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-3397
- The paper
- Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., Ma, X., Liu, C., Liu, S., Lian, Z.-X., & Yang, Z. (2019). Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-3397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.